Rollout of the First-Ever Blood Test for Alzheimer's Detection by Unilabs and C2N Diagnostics

Unilabs and C2N Diagnostics have announced a collaboration to launch the first-ever blood test for Alzheimer's disease detection in 75 countries. This partnership aims to enhance diagnostic processes for Alzheimer's by providing a less invasive and more accessible option for early detection.

The Blood Test

Alzheimer’s disease, which affects millions globally, has traditionally required lengthy, invasive, and costly diagnostic procedures. The introduction of the Precivity blood test, designed for individuals aged 55 and older, may constitute significant progress in the field.

This test detects pathological indicators such as amyloid plaques and neurofibrillary "tau" tangles, which are associated with Alzheimer’s disease. By identifying these markers early, healthcare providers can diagnose the disease sooner, allowing for earlier and more effective treatment.

The Precivity portfolio from C2N Diagnostics includes blood tests that utilize specialized laboratory technologies to measure proteins associated with Alzheimer's disease. These tests provide a clinically validated score that indicates the likelihood of brain amyloid plaques. Similar to amyloid PET scans or cerebrospinal fluid testing, these blood tests offer a non-invasive diagnostic alternative for healthcare providers.

See also: Companies Driving Innovation To Fight Alzheimer’s Disease

Technology Transfer and Future Plans

The agreement includes a technology transfer to integrate C2N’s Alzheimer’s blood biomarkers into Unilabs’ network across Europe. This transfer ensures that Precivity testing maintains the same quality and accuracy as provided by C2N’s central lab in St. Louis, Missouri.

The PrecivityAD and PrecivityAD2 blood tests have received regulatory approvals in the European Union and the United Kingdom. These tests are designed for patients with mild cognitive impairment or dementia and are available through qualified healthcare providers.

The multi-year agreement between Unilabs and C2N Diagnostics will make the Precivity tests available in Europe, including Norway, Switzerland, and the United Kingdom, as well as in Peru, Saudi Arabia, and the United Arab Emirates. This initiative addresses the need for advanced diagnostic tools in regions where access has been limited.

Topics: HealthTech